NSCLC

You have access
Profiling of Vascular Endothelial Growth Factor Receptor Heterogeneity Identifies Protein Expression-defined Subclasses of Human Non-small Cell Lung Carcinoma
TIMOTHY R. HOLZER, ANGIE D. FULFORD, LESLIE O'NEILL REISING, DREW M. NEDDERMAN, XUEKUI ZHANG, LAURA E. BENJAMIN, ANDREW E. SCHADE and AEJAZ NASIR

Anticancer Research July 2016, 36 (7) 3277-3288;
You have access
Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib
ONDREJ FIALA, MILOS PESEK, JINDRICH FINEK, ONDREJ TOPOLCAN, JAROSLAV RACEK, MARTIN SVATON, RADEK KUCERA, MAREK MINARIK, LUCIE BENESOVA, ZBYNEK BORTLICEK, RENATA CHLOUPKOVA, ALEXANDR POPRACH and TOMAS BUCHLER

Anticancer Research May 2016, 36 (5) 2459-2465;
You have access
PIK3CA Mutations Detected in Patients with Central Nervous System Metastases of Non-small Cell Lung Cancer
MARCIN NICOŚ, PAWEŁ KRAWCZYK, TOMASZ POWRÓZEK, PAULINA SZUDY, BOŻENA JAROSZ, MAREK SAWICKI, JUSTYNA SZUMIŁO, TOMASZ TROJANOWSKI and JANUSZ MILANOWSKI

Anticancer Research May 2016, 36 (5) 2243-2249;
You have access
Discovery of Novel (Imidazo[1,2-a]pyrazin-6-yl)ureas as Antiproliferative Agents Targeting P53 in Non-small Cell Lung Cancer Cell Lines
MARC-ANTOINE BAZIN, BÉNÉDICTE ROUSSEAU, SOPHIE MARHADOUR, CHRISTOPHE TOMASONI, PIERRE EVENOU, SYLVIE PIESSARD, ABRAHAM J. VAISBERG, SANDRINE RUCHAUD, STÉPHANE BACH, CHRISTOS ROUSSAKIS and PASCAL MARCHAND

Anticancer Research April 2016, 36 (4) 1621-1630;
You have access
The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy
MARTIN SVATON, ONDREJ FIALA, MILOS PESEK, ZBYNEK BORTLICEK, MAREK MINARIK, LUCIE BENESOVA and ONDREJ TOPOLCAN

Anticancer Research March 2016, 36 (3) 1077-1082;
You have access
The Effect of Payer Status on Survival of Patients with Stage I/II Non-small Cell Lung Cancer: NCDB 1998-2011
RUNHUA SHI, RICHIE DIAZ, ZHENZHEN SHI, ELIZABETH DUVALL and GLENN MILLS

Anticancer Research January 2016, 36 (1) 319-326;
You have access
Pemetrexed Versus Erlotinib in the Second-line Treatment of Patients with Advanced-stage Non-squamous NSCLC Harboring Wild-type EGFR Gene
ONDREJ FIALA, MILOS PESEK, JINDRICH FINEK, MARTIN SVATON, MAREK MINARIK, LUCIE BENESOVA, ZBYNEK BORTLICEK, RADEK KUCERA and ONDREJ TOPOLCAN

Anticancer Research January 2016, 36 (1) 447-453;
You have access
Prognostic Significance of Serum Tumor Markers in Patients with Advanced-stage NSCLC Treated with Pemetrexed-based Chemotherapy
ONDREJ FIALA, MILOS PESEK, JINDRICH FINEK, MARTIN SVATON, ONDREJ SOREJS, ZBYNEK BORTLICEK, RADEK KUCERA and ONDREJ TOPOLCAN

Anticancer Research January 2016, 36 (1) 461-466;
You have access
Potential of Amifostine for Chemoradiotherapy and Radiotherapy-associated Toxicity Reduction in Advanced NSCLC: A Meta-Analysis
ANNEMARIE DEVINE and LAURE MARIGNOL

Anticancer Research January 2016, 36 (1) 5-12;
You have access
Immunotherapies for NSCLC: Are We Cutting the Gordian Helix?
WOLFRAM C.M. DEMPKE, LUDGER SELLMANN, KLAUS FENCHEL and KLAUS EDVARDSEN

Anticancer Research November 2015, 35 (11) 5745-5757;

Main menu

User menu

Search

NSCLC

Pages